family with sequence similarity 182 member AGenealiases: C20orf91 · C20orf91A
Q-omics provides the consensus-scored FAM182A profile across patient tissues and cancer cell-line models. FAM182A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM182A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FAM182A RNA expression shows 14,017 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where FAM182A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM182A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM182A survival associations across molecular data types. FAM182A RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM182A RNA expression–survival associations across cancer types. High FAM182A expression shows unfavorable associations in KIRP, but favorable associations in KIRC, LGG, HNSC, READ and THYM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM182A RNA expression.
This table summarizes FAM182A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM182A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM182A shows lower tumor expression in THCA, LUAD, BRCA and HNSC and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher FAM182A RNA expression in tumor versus normal tissue (log2 FC = +0.133, t-test p < 0.001).
This table shows molecular features associated with FAM182A in patient tissues and cancer cell lines. In patient samples, FAM182A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM182A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
